Electroporation of Synthetic DNA Antigens Offers Protection in Nonhuman Primates Challenged with Highly Pathogenic Avian Influenza Virus
- 1 May 2009
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 83 (9) , 4624-4630
- https://doi.org/10.1128/jvi.02335-08
Abstract
Avian influenza highlights the need for novel vaccination techniques that would allow for the rapid design and production of safe and effective vaccines. An ideal platform would be capable of inducing both protective antibodies and potent cellular immune responses. These potential advantages of DNA vaccines remain unrealized due to a lack of efficacy in large animal studies and in human trials. Questions remain regarding the potential utility of cellular immune responses against influenza virus in primates. In this study, by construct optimization and in vivo electroporation of synthetic DNA-encoded antigens, we observed the induction of cross-reactive cellular and humoral immune responses individually capable of providing protection from influenza virus infection in the rhesus macaque. These studies advance the DNA vaccine field and provide a novel, more tolerable vaccine with broad immunogenicity to avian influenza virus. This approach appears important for further investigation, including studies with humans.Keywords
This publication has 31 references indexed in Scilit:
- A consensus–hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza virusesProceedings of the National Academy of Sciences, 2008
- An Adjuvanted, Low‐Dose, Pandemic Influenza A (H5N1) Vaccine Candidate Is Safe, Immunogenic, and Induces Cross‐Reactive Immune Responses in Healthy AdultsThe Journal of Infectious Diseases, 2008
- Deaths from Bacterial Pneumonia during 1918–19 Influenza PandemicEmerging Infectious Diseases, 2008
- Heterosubtypic Protection against Pathogenic Human and Avian Influenza Viruses via In Vivo Electroporation of Synthetic Consensus DNA AntigensPLOS ONE, 2008
- Vaccination of Macaques with Adjuvanted Formalin-Inactivated Influenza A Virus (H5N1) Vaccines: Protection against H5N1 Challenge without Disease EnhancementJournal of Virology, 2008
- Human and Avian Influenza Viruses Target Different Cells in the Lower Respiratory Tract of Humans and Other MammalsThe American Journal of Pathology, 2007
- Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: An international collaborative studyVaccine, 2007
- Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virusNature, 2006
- Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trialThe Lancet, 2006
- Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccineVirus Research, 2004